Cerebral cavernous malformation (CCM) is a neurovascular familial or sporadic disease that is characterised by capillary-venous cavernomas, and is due to loss-of-function mutations to any one of three CCM genes. Familial CCM follows a two-hit mechanism similar to that of tumour suppressor genes, while in sporadic cavernomas only a small fraction of endothelial cells shows mutated CCM genes. We reported that in mouse models and in human patients, endothelial cells lining the lesions have different features from the surrounding endothelium, as they express mesenchymal/stem-cell markers. Here we show that cavernomas originate from clonal expansion of few Ccm3-null endothelial cells that express mesenchymal/stem-cell markers. These cells then attract surrounding wild-type endothelial cells, inducing them to express mesenchymal/stem-cell markers and to contribute to cavernoma growth. These characteristics of Ccm3-null cells are reminiscent of the tumour-initiating cells that are responsible for tumour growth. Our data support the concept that CCM has benign tumour characteristics.
Cerebral cavernous malformation (CCM) is a vascular disease that is characterised by capillary–venous cavernomas. These malformations are almost exclusively located in the central nervous system and they can cause micro bleeds that can lead to epileptic seizures and cerebral haemorrhage1,2,3,4,5. CCM occurs in familial and sporadic forms. Familial cases follow autosomal-dominant inheritance due to loss-of-function mutations in one of the three genes known as CCM1/KRIT1, CCM2/malcavernin or CCM3/PDCD10. The inherited forms of CCM develop multiple vascular lesions that tend to increase in number and size with age. In contrast, the sporadic form of CCM is characterised by only a single lesion. This difference in the lesion burden between familial and sporadic CCM suggests that CCM pathogenesis might follow a two-hit, biallelic molecular mechanism that is similar to that seen for tumour-suppressor genes. Moreover, a remarkable feature of familial CCM is that, although all of the endothelial cells have a heterozygote loss-of-function mutation to one of the three CCM genes, the malformations are only found in a few localised regions of the brain microcirculation. Furthermore, it has been shown that, for human sporadic cavernomas, only a small fraction of endothelial cells have a null mutation for the CCM genes6,7,8,9. Considering that the double hit is a rare event, this suggests that a small number of mutated endothelial cells appear to be enough to trigger the malformations.
In our previous studies, we reported that in mouse models of CCM and in human patients the endothelial cells lining cavernomas have different features than the surrounding endothelial cells of the same vessel. Specifically, the endothelial cells in the lesions show a mixed phenotype that combines both endothelial and mesenchymal features in a way similar to endothelial cells that are undergoing endothelial-to-mesenchymal transition (EndMT). Most importantly, these cells also express a relatively large set of stem cell markers (e.g., Cd44, Id1, Slug, Klf4, Sca1)10,11,12,13,14. These characteristics are reminiscent of the so-called tumour-initiating cells or tumour stem cells that are responsible for tumour growth and metastatic differentiation15,16,17.
We show here that cavernomas originate from clonal expansion of a small number of Ccm3−/− endothelial cells that express EndMT and progenitor markers. These cavernoma-initiating cells can attract the surrounding wild-type endothelial cells and induce their mesenchymal transition, coinciding with a strong and time-dependent increase in the size of the cavernomas. Our findings support the concept that CCMs have benign tumour characteristics and are consistent with the observations of mosaicism in human cavernomas. Furthermore, data indicate that a minimal proportion of Ccm3-null endothelial cells can induce large-sized malformations, as in the human disease8,9. This concept is also in agreement with the fact that Ccm3 is a tumour suppressor18,19 and its deletion may be correlated to benign brain tumours20.
Cavernomas have clonal origin
To follow the clonal expansion of endothelial cells, we took advantage of the Cdh5(PAC)-Cre-ERT2/R26R-Confetti mouse that carries the stochastic and multicolour reporter Brainbow2.1 in the R26 locus (R26R-Confetti21,22) and the inducible Cre-ERT2 recombinase that is driven by the endothelial-specific promoter of VE-cadherin (Cdh5(PAC)-Cre-ERT2)23. After a single injection of tamoxifen, this Cre-mediated recombination promotes endothelial cells to randomly express any one of the four fluorescent proteins to form a mosaic (Fig. 1a, b). To study whether the CCM lesions have a clonal origin, the Cdh5(PAC)-Cre-ERT2/R26R-Confetti mice were crossed with Ccm3f/f mice (Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti), which develop CCM lesions upon tamoxifen injection that resemble the human pathology24.
Injection of tamoxifen on postnatal day 1 (P1) induced deletion of the Ccm3 gene and expression of one of the four fluorescent proteins in an endothelium-specific manner. By P8, the retina showed vascular malformation at the front, with large areas of clonal expansion (Fig. 1a). In the cerebellum, where most of the cavernomas were formed in this model (Fig. 1b, f), the majority of the small lesions appeared to be composed of cells of the same colour, which thus suggested their clonal origin. Larger lesions had a more complex composition, with clonal areas surrounded by regions with endothelial cells of mixed colours (Fig. 1b–f and Supplementary Movies 1–6). This suggested that, after the first clonal growth, the adjacent lesions might fuse or that surrounding cells might be recruited into the lesion.
The clonal expansion presupposes an increased cell proliferation of Ccm3−/− cells within the lesions, as we have previously shown in vivo24. Ccm3 is known to have a pivotal role in regulating cell survival and cell death, and anti-apoptotic25,26,27 as well as pro-apoptotic28,29,30,31 functions have been reported in different cell types. Nevertheless, whether the increase in cell proliferation of endothelial cells lining the cavernomas is directly dependent on loss of Ccm3 is not completely understood. Here we show that the loss of Ccm3 is sufficient to increase the proliferation rate of endothelial cells and to drive the entrance into the S-phase, while the re-expression of the gene decreased cell proliferation to wild-type level (see Supplementary Figs. 1, 2, 13 and 14 for more details).
In parallel, we have tested the activated caspase 3 protein levels in both Ccm3+/+ and Ccm3−/− conditions and we have not seen any significant difference, arguing that the deletion of Ccm3 could not be sufficient to inhibit the endothelial cell apoptosis under physiological conditions.
Large cavernomas are mosaics
This ‘fast progression’ acute mouse model of Ccm3−/− CCM is lethal in around 12 days, and it does not allow detailed analysis of the temporal steps of cavernoma formation. To overcome this limitation, we generated a slow progression model (i.e. chronic) of Ccm3−/− CCM by giving a low dose of tamoxifen to these Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice (Fig. 2 and Supplementary Movie 7), and we analysed them at different developmental stages (i.e. P8, P14 and P30). Under this condition, the mice reached adulthood, and as in the human CCM disease, only a small proportion of the cells (<15%) showed Ccm3 deletion (Supplementary Figs. 3a, 11 and 12).
In the acute model, the lesions were preferentially located in the cerebellum and retina, while in the chronic model they were also in other brain regions, including the hippocampus and the olfactory bulb, similar to the human disease32,33 (Fig. 2e).
While the number of lesions remained substantially constant over time, at P14 and P30 the mean area, and thus the total lesioned area, strongly increased (Fig. 2f–h).
Taking all of these characteristics into account, the chronic model appears to be more suitable for studies on the progression of human cavernomas.
In the chronic model of the Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice, not all the endothelial cells lining the large cavernomas were Confetti positive; i.e. Ccm3−/−. In contrast, most of the endothelial cells were Confetti negative, and therefore they had not undergone Ccm3 recombination (Fig. 3a–d and Supplementary Movie 8).
The stochastic nature of the recombination in the Confetti system cannot exclude that, by chance, two adjacent cells express the same colour without deriving by the same cell. In order to assess the frequency of this event, and to better quantify the clonal expansion within the lesions, we performed a more quantitative analysis on cerebellum from Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice and their Ccm3+/+ counterpart after injection of low tamoxifen at P2 (Fig. 3e–g, Supplementary Fig. 4). We considered a clone any group of contiguous cells expressing the same colour within a vessel and counted the number of cells that composed the clone. In the vessels of Ccm3+/+ mice, the average size of clones was 1.14 ± 0.016 cells, with 88% of single cells and no clone >4 cells. Likewise, in normal vessels of the Ccm3−/−, the average size of clones was 1.19 ± 0.014 cells, with 85% of single cells and no clone >4 cells. Within the lesions instead, the clones showed an average size of 9.35 ± 0.867 cells, with 43% of clones >4 cells. Moreover, around 12% of clones had a size from 10 up to 60 cells. A small fraction of clones of more than one cell (i.e. two or three cells) within normal vessels could be explained by either cell division (which can be expected in a developing vasculature) or the chance that two adjacent cells express the same colour. The presence of clones of significantly larger size, i.e. ten or more cells, however, strongly support the concept that an unusual expansion has occurred.
The quantification also showed that there is no different distribution of the four fluorophores between lesions and normal vessels and that the CFP is slightly under represented among the four fluorescent proteins (Fig. 3e).
Fluorescence-activated cell sorting (FACS) analysis of endothelial cells isolated from the Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice treated with low tamoxifen showed that only 11.0 ± 7.4% endothelial cells underwent recombination of Ccm3 (Supplementary Fig. 3a). In addition, quantitative real-time polymerase chain reaction (RT–qPCR) confirmed that endothelial cells positive for Confetti also showed recombination for the Ccm3 gene, while the Confetti-negative cells expressed the same level of Ccm3 transcript as the wild-type endothelial cells (Supplementary Fig. 3b). Overall, these data support the concept that, after the initial clonal expansion of a few endothelial cells that have undergone recombination, further development of the cavernomas was promoted by recruiting Ccm3+/+ cells that had not undergone recombination (i.e. wild-type endothelial cells).
In the acute model, a large proportion of the endothelial cells (>80%) had biallelic inactivation of one of the Ccm genes, but only the cells that lined the cavernomas showed EndMT markers24,36. Double immunostaining for endothelial (ERG1, COLLAGEN IV, PECAM1) and EndMT markers (i.e., FSP1, pSMAD3, ID1, FN1, SCA1, αSMA, KLF4) in the chronic model showed that at early stage (P8) small lesions are composed mostly by endothelial cells that expressed higher levels of EndMT markers if compared to cells of surrounding normal vessels, while at later stages (P14), in larger cavernomas only a subset of endothelial cells underwent EndMT (Fig. 4).
At P8, almost 100% of the endothelial cells that lined the cavernomas were KLF4-positive (i.e. bona fide endothelial cells undergoing EndMT), which then declined during the increase in the size of the cavernomas to 70% KLF4-positive cells at P14 and 40% KLF4-positive cells at P30 (Fig. 4b).
To further confirm this data, we crossed Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice with a different reporter mouse, for R26-EYFP, which is widely used for cell tracking37. With this reporter, mosaicism of the recombination of the endothelial cells lining the lesions was confirmed, with a progressive increase of EYFP-negative, i.e. Ccm3+/+, endothelial cells being recruited into the large cavernomas (Fig. 5a). Moreover, co-immunostaining demonstrated that the cells lining the cavernomas and undergoing EndMT transition had an endothelial origin (Fig. 5b–f), as they also expressed the EYFP. The wild-type endothelial cells that were recruited into the lesions also overexpressed EndMT markers, including KLF4, ID1, pSMAD3, SCA1 and αSMA (Fig. 5b–f).
Ccm3 −/− cells recruit Ccm3 +/+ endothelial cells
To further prove that Ccm3−/− cells can form cavernomas and recruit surrounding Ccm3+/+ cells, we isolated endothelial cells from acute P7 Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice and we injected these cells into the brains of adult wild-type mice. After 4 days, Ccm3−/− Confetti-positive cells formed abnormal vessels that comprised also Confetti-negative cells (Fig. 6a, b). In order to confirm the recruitment of Ccm3+/+ cells by injecting Ccm3−/− cells, we isolated endothelial cells from acute P7 Cdh5(PAC)-Cre-ERT2/Ccm3f/f, Confetti negative mice and injected them in Cdh5(PAC)-Cre-ERT2/R26R-Confetti adult mice. Here also, Ccm3−/− cells generated abnormal vessels that recruited Confetti-positive, thus Ccm3+/+, endothelial cells of the host (Fig. 6c, d) In parallel, we engrafted the same Ccm3−/− cells in a Matrigel plug subcutaneously into Cdh5(PAC)-Cre-ERT2/R26R-Confetti mice. After 10 days, the injected Ccm3−/− endothelial cells formed abnormal vessels and recruited Confetti-positive endothelial cells coming from the host (Fig. 6e, f). Overall these data confirmed that Ccm3−/− endothelial cells were able to form CCM lesions and to recruit normal surrounding cells when implanted in a wild-type context.
To investigate the mechanism(s) that regulates the cross-talk between these Ccm3−/− and Ccm3+/+ cells in greater depth, we developed a set of in vitro assays. First, we co-cultured Ccm3+/+ and Ccm3−/− immortalised endothelial cells. When cultured alone, both the Ccm3+/+ and Ccm3−/− cells formed a typical endothelial monolayer (Supplementary Fig. 5c, d). However, when the Ccm3−/− cells were mixed with the Ccm3+/+ cells they progressively formed spheroids while the Ccm3+/+ endothelial cells still grew in a monolayer (Fig. 7a, b; Supplementary Fig. 6). These spheroids were composed of 26.8 ± 3.19% Ccm3+/+ cells. In the areas of close contact, the Ccm3+/+ cells became integrated into the Ccm3−/− spheroids. Time-lapse movies confirmed that the wild-type (i.e. Ccm3+/+) cells were actively recruited into the Ccm3−/− spheroids, rather than just being entrapped through physical interactions (Supplementary Movie 9). Moreover, when the established spheroids were detached and placed onto a new Ccm3+/+ cell monolayer, these new wild-type cells were actively recruited and entered the spheroids (Fig. 7c–e; Supplementary Fig. 7). Time-lapse movies of wound-healing experiments showed the different migration behaviours of these Ccm3+/+ and Ccm3−/− cells (Supplementary Fig. 8a, b, and Supplementary Movie 10). These also showed that, as soon as the Ccm3+/+ cells came into contact with the Ccm3−/− cells, they acquired mesenchymal features, with filopodia that protruded into the Ccm3−/− monolayer (Supplementary Fig. 8c–d, and Supplementary Movies 10 and 11).
Ccm3 −/− cells induce EndMT in Ccm3 +/+ endothelial cells
As well as being recruited by the Ccm3−/− cells, the Ccm3+/+ cells were stimulated to undergo EndMT. The Ccm3+/+ cells that were isolated from these spheroids expressed higher levels of the EndMT markers Fsp1, Cd44 and Fn1 and decreased levels of the endothelial-specific Claudin5, as compared to non-recruited Ccm3+/+ cells that remained as monolayer at the bottom (Fig. 7g). To exclude that the upregulation of EndMT markers was merely due to the fact that they grew in three-dimensional (3D), we cultured Ccm3+/+ alone as spheroids on a methylcellulose matrix and compared their gene expression to the same cells cultured as monolayer (Supplementary Fig. 9). After 7 days, the cells cultured as spheroids showed no increase of Fn1 and Claudin5 and a slight increase of Cd44, which was not comparable to the one induced by the co-culture with Ccm3−/− cells. Only Fsp1 showed a significant upregulation under 3D conditions. Therefore, we can assess that the molecular modifications of recruited Ccm3+/+ cells are mostly induced by the presence of Ccm3−/− cells rather than by the 3D culture itself. Moreover, the induction of EndMT by the co-culture was reversible, as once the Ccm3+/+ cells isolated from the spheroids were put back in culture alone, they reverted to the expression level of the Ccm3+/+ cells cultured as monolayer (Supplementary Fig. 9).
We also asked whether the EndMT phenotype induced by the deletion of Ccm3 could be rescued by re-expression of the gene. To this aim, we infected Ccm3−/− cells with a lentiviral vector that expresses the human CCM3 gene fused to EGFP (Supplementary Fig. 1), to generate a reconstituted cell line (Ccm3−/−-hCCM3-EGFP). Interestingly, the Ccm3−/−-hCCM3-EGFP cells reverted to wild-type phenotype in terms of proliferation rate (Supplementary Fig. 1), morphology, adherens junctions and expression of EndMT markers (Supplementary Fig. 1).
Furthermore, conditioned medium from these Ccm3−/− cells increased the migration rates of Ccm3+/+ cells (Fig. 7f) and induced them to upregulate their EndMT markers (Fig. 7h), compared to the negative control of conditioned medium from Ccm3+/+ cells.
Taken together, these data support the concept that Ccm3−/− cells can attract Ccm3+/+ cells and induce them to undergo EndMT, as it has also been reported in vivo. The data on the effects of this conditioned medium here (Fig. 7f) suggested that secreted soluble factors are involved in the Ccm3−/−-cell-mediated recruitment of the Ccm3+/+ endothelial cells in cooperation with direct interaction of Ccm3−/− and Ccm3+/+ cells.
We reported previously that Ccm1−/− cells produce high amounts of BMP6 and show significant phosphorylation of SMAD2/3 and SMAD1/536,38 also under resting conditions. Furthermore, stimulation of wild-type endothelial cells with BMP6 induced upregulation of their EndMT markers, which was inhibited by the BMP pathway general inhibitor DMH136,39. Last but not least, BMP6 is a strong inducer of endothelial chemotaxis40,41.
Here also, these Ccm3−/− cells expressed high levels of BMP6 and showed increased phosphorylation of SMAD1 and SMAD3 (Supplementary Fig. 10a). The treatment of the Ccm3+/+ cells with BMP6 promoted upregulation of the EndMT markers Klf4, Sca1, Fsp1, Cd44 and Id1 (Supplementary Fig. 10d), which was blocked by bone morphogenetic protein (BMP) inhibition. Moreover, BMP6 increased the migration rates of wild-type (i.e. Ccm3+/+) cells and the BMP inhibitors blocked this effect (Supplementary Fig. 10e). Consistent with this, in a wound-healing assay, treatment with the BMP inhibitor DMH1 blocked the increased migration rate induced by Ccm3−/−-cell-conditioned medium (Fig. 7f).
Overall, these data are suggestive of a role of BMP6, possibly in combination with other inflammatory cytokines, in the attraction of wild-type endothelial cells in the cavernomas by Ccm3−/− cells.
Endothelial progenitors are involved in cavernoma formation
We have shown that cavernomas originate from clonal expansion of Ccm3−/− endothelial cells that co-express endothelial and mesenchymal/stem cell markers and trigger the recruitment of Ccm3+/+ endothelial cells. Recently, vessel-resident endothelial progenitors have been identified and characterised on the basis of the expression of different markers10,12,42,43, which included Cd157/Cd20044, Procr45 and Peg3/PW146. These progenitors co-expressed endothelial and mesenchymal/stem cell markers and underwent clonal expansion to generate new blood vessels34.
Taking into consideration the strong similarities with other tissue stem cells, it is tempting to speculate that the early steps of cavernoma formation are due to the clonal expansion of resident endothelial progenitors. This is supported by the endothelial cells in the early lesions, which express most of the stem/progenitor markers, including Id1, Sca1, Cd44 and Klf4, and more interestingly, also the specific endothelial progenitor marker Protein C Receptor (Procr; Fig. 8a, b). Furthermore, it has been shown that the number of endothelial progenitors declines with the age of these mice, as higher numbers in neonates and almost undetectable levels in adults,46 which is consistent with the decline in the number of CCM malformations that form when Ccm3 is deleted at later time points after birth24,47. Here we confirmed by FACS analysis that Procr is expressed in a small population, 4.4 ± 1.5%, of brain endothelial cells in wild-type mice at P2 (Fig. 8d), which is consistent with what is already reported in other tissues45. Moreover, RNAseq analysis made on endothelial cells from the wild-type brains48 showed that the expression of Procr decreases over time after birth (Fig. 8e).
To further test this hypothesis, we asked whether inactivation of Ccm3 in progenitor cells would specifically induce their clonal expansion and early steps of CCM development. To this end, we crossed the Ccm3f/f mice with the ProcrCreERT2-IRES-tdTomato/+ knock-in mouse model, in which a CreERT2-IRES-tdTomato cassette is driven by the promoter of Procr45,49. The ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f mouse model allowed induction of the tamoxifen-dependent Ccm3 deletion specifically in Procr+ endothelial progenitors.
After recombination, the mice developed lesions both in the retina and the cerebellum (Fig. 8c), in a way that recapitulates the formation of lesions in the chronic model. By crossing the ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f mouse model with the R26-EYFP reporter, we confirmed that the lesions were composed of EYFP+ cells, thus originating from Procr+ endothelial progenitors (Fig. 8f). Finally, the endothelial cells lining the cavernomas overexpressed EndMT markers if compared to the cells of surrounding normal vessels (Fig. 8g–j), thus resembling the pathogenesis already shown by the Cdh5(PAC)-Cre-ERT2/Ccm3f/f model.
These data thus support the idea that endothelial progenitors are responsible for the triggering of cavernoma formation upon Ccm3 deletion.
Taken together, our data explain some of the crucial aspects of the development and evolution of CCM, while also opening novel therapeutic opportunities. Using a slowly evolving Ccm3−/− model system, we have demonstrated that, upon induction of homozygote Ccm3 mutation, only a few of the endothelial cells undergo clonal expansion and attract Ccm3+/+ cells, which, in turn, contribute to the growth of the malformations. This is in agreement with the human disease, where following a double-hit process6,7,8,9, a few heterozygote endothelial cells acquire homozygosity for the Ccm gene inactivation and trigger the formation of cavernomas. Consistently in both mice and humans, the endothelial cells lining the lesion appear as a mosaic, i.e. formed by both mutated and wild-type cells. Therefore, an important event in the evolution of the cavernomas appears to be the attraction of Ccm3+/+ cells by Ccm3−/− cells, which, in turn, strongly contribute to the growth of the malformation.
An important question here is whether or not the occurrence of the malformations is a stochastic event, i.e. all endothelial cells have the potential to undergo clonal expansion and EndMT upon Ccm3 mutation in a random way. Alternatively, once mutated in Ccm3, only a subset of the cells might trigger the formation of lesions. This second possibility has been described in cancer, where tumour-initiating cells are responsible for metastatic dissemination and clinical relapse in a variety of cancers43,50. Tumour-initiating cells have similarities to normal tissue stem cells and undergo epithelial-to-mesenchymal transition. It is therefore attractive to hypothesise that, also in CCM, the cavernomas are triggered by a few mutated endothelial cells with characteristics and markers specific of endothelial-resident progenitors, such as Cd157+, Procr+ and PW1+. As in tumours, these cells would then recruit wild-type cells, which will, in turn, contribute to the growth of the cavernomas. Therefore, with these cavernoma-initiating cells normally present along the vessels, we propose a model in which upon loss of Ccm3 they undergo clonal expansion to form malformations. In a further step, the mutated cells recruit wild-type cells, which, in turn, strongly contribute to cavernoma growth (Fig. 9). Taking advantage of the ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f mouse model, we have also shown that resident endothelial progenitors can trigger the formation of cavernomas upon deletion of Ccm3. We cannot completely exclude that these cavernoma-initiating cells are recruited systemically, as a bone marrow transplantation is not possible on new-born mice. However, the data presented here support the idea that cavernomas originate from Procr+ progenitors, which have been described to reside in pre-existing vessels rather than being recruited45 from circulating cells.
Broadly, our findings are suggestive of new possibilities for therapeutic intervention for patients with CCM, such as through inhibition of endothelial chemokines, to prevent the recruitment of wild-type endothelial cells or, more drastically, through identification and suppression of these cavernoma-initiating cells.
Antibodies and reagents
Tamoxifen was from Sigma-Aldrich, and Vectashield without and with DAPI were from Vector Laboratories. The following primary antibodies were used: Cd31 APC-conjugated anti-PECAM1 (1:50; 551262; BD Pharmingen); rabbit anti–phospho-Smad1/5 (Ser463/465) monoclonal (1:1000; 9516; Cell Signaling); rabbit anti-SMAD1 polyclonal (1:1000; 9743; Cell Signaling); rabbit anti–phospho-SMAD3 (Ser423/425) monoclonal (1:1000 for WB, 1:200 for IF; ab52903; AbCam); rabbit anti-SMAD3 monoclonal (1:1000; 9523; Cell Signaling); mouse anti-BMP6 (1:1000; Ab15640; AbCam); mouse anti-vinculin monoclonal (1:5000; V9264; Sigma-Aldrich); rabbit anti-Fsp1 polyclonal (1:200; 07-2274; Merck Millipore); Armenian hamster anti-Cd31 monoclonal (1:400; MAB1398Z; Merck Millipore); rat anti-Cd31 monoclonal (1:200; 553370 BD Biosciences); rabbit anti-Fn1 polyclonal (1:200; ab23750; AbCam); rat anti-Sca1 monoclonal (1:200; ab51317; AbCam); rabbit anti-Id1 polyclonal (1:200; sc-488; Santa Cruz); rabbit anti-Erg1/2/3 polyclonal (1:200; sc-353; Santa Cruz Biotechnology); goat anti-Podocalyxin polyclonal (1:300; AF1556; R&D Systems); goat anti-Klf4 polyclonal (1:200; AF3158; R&D Systems); rabbit anti-collagen IV polyclonal (1:200; 2150-1470; Bio-Rad); rabbit anti-GFP polyclonal (1:300; A-6455; ThermoFisher); and mouse anti–α-SMA Cy3-conjugated monoclonal (1:500; C6198; Sigma-Aldrich); Goat anti-VE-Cadherin (C-19) (1:200; sc-6458; Santa Cruz Biotechnology). For immunofluorescence, the secondary antibodies were produced in either donkey or goat and targeted against the appropriate species, with conjugation with AlexaFluor 405, 488 or 647 or with Cy3 (1:400; Jackson Laboratories). For the whole-mount retina, the vessels were stained with biotinylated Isolectin B4 (1:100; B-1205; Vector Laboratories, Burlingame, CA, USA) and then with streptavidin conjugated with AlexaFluor 488, 555 or 647 (1:500; Invitrogen). For western blotting, horseradish peroxidase (HRP)-linked anti-mouse and anti-rabbit antibodies were used (1:2000; Cell Signaling). For the FACS analysis, the following primary antibodies were used: rat anti-Ki67 (1:100; 14-5698-82 clone SolA15, Invitrogen); purified mouse anti-BrdU (1:5; 347580, BD Bioscience); rabbit anti-PPH3 Ser10 (1:100; 06-570, Millipore).
The following reagents were also used: DMH1 (D8946; Sigma-Aldrich); K02288 (SML1307; Sigma-Aldrich), and recombinant BMP6 (507-BP-020; R&D systems); Propidium Iodide (PI; P4864, Sigma-Aldrich) and BrdU (B92285-1G, Sigma-Aldrich); Ribonuclease A from bovine pancreas (RNase A. cod.9001-99-4, Sigma-Aldrich), Erythrosin B, 0.1% solution in PBS (200964-25G, Sigma-Aldrich); Avertin (T48402; Sigma), Acrylamide (1610140; Biorad), VA-044, 2,2'-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (A3012; TCI chemicals), Microwave reaction vials (351521; Biotage), Microwave reaction vials cap with septum (352298; Biotage), Hystodenz (D2158; Sigma).
pmCherry-N1 vector was purchased from Clontec (Cat #632523). LifeAct-EGFP was a kind gift from Professor Wedlich-Söldner (WWU-Münster, Münster, Germany). FUGW, pCMV-delta R8.2 and pMD2.G were purchased from (Addgene, Cambridge, MA 02139, USA). The AgeI, BsrgI, XbaI and NheI restriction enzymes were from New England Biolabs. Phalloidin-TRITC (Tetramethyl rhodamine Isothyocyanate) and Phalloidin-AlexaFluor488 were from Thermo Fisher Scientific.
The Lenti ORF clone of mGFP-tagged Human programmed cell death 10 (PDCD10), transcript variant 3 was purchased from (OriGene Technologies Inc., Rockville, MD 20850 USA).
The following mouse strains were used: Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice in which Ccm3f/f mice with exons 4–5 of the Ccm3 gene flanked by loxP sites (Taconic Artemis GmbH) were bred with Cdh5(PAC)-Cre-ERT2 mice to obtain endothelial-specific and tamoxifen-inducible loss of function of the Ccm3 gene, as previously described24. The Cdh5(PAC)-Cre-ERT2 mouse line was kindly provided by R.H. Adams (Department of Tissue Morphogenesis, Faculty of Medicine, Max Planck Institute for Molecular Biomedicine University of Münster, Münster, Germany). Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26-EYFP mice were generated by crossing Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice with the Rosa26-Stopfl-EYFP reporter mice24,36,37,38, to monitor tamoxifen-induced Cre/loxP recombination. The Rosa26‐Stopfl‐EYFP mice were kindly donated by Dr. S. Casola (FIRC Institute of Molecular Oncology, Milan, Italy). For the Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice, Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice were crossed with the stochastic multicolour reporter R26R-Confetti mice that allows clonal expansion by recombination of cells to be followed21. The ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f mice were generated by crossing Ccm3f/f mice with ProcrCreERT2-IRES-tdTomato/+ knock-in mice, in which a CreERT2-IRES-tdTomato cassette is driven by the promoter of Procr45,49, which allows induction of recombination in Procr-positive cells. ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f mice were then crossed with the Rosa26-Stopfl-EYFP reporter mice to generate ProcrCreERT2-IRES-tdTomato/+/Ccm3f/f/R26-EYFP mice.
All the procedures with the mice were performed in agreement with the Institutional Animal Care and Use Committee (IACUC) of FIRC Institute of Molecular Oncology, in compliance with the guidelines established in the Principles of Laboratory Animal Care (Directive 86/609/EEC) and approved by the Italian Ministry of Health.
Tamoxifen was dissolved in ethanol to 100 mg/ml and then diluted in corn oil to the final concentration of either 2 or 0.1 mg/ml. For the ‘acute’ model, 1-day-old mouse pups received a single intragastric injection of 50 μl 2 mg/ml tamoxifen (final dose: 100 μg per mouse). For the ‘chronic’ model, 2-day-old mouse pups received a single intragastric injection of 50 μl 0.1 mg/ml tamoxifen (final dose: 5 μg per mouse).
Immunohistochemistry and confocal microscopy
For the retinal vasculature, mouse eyes were fixed in 4% paraformaldehyde (PFA) for 2 h prior to dissection. Whole-mount retinas were incubated overnight with primary antibodies diluted in 10% donkey serum, 1% bovine serum albumin (BSA) and 0.5% Triton-X100 in phosphate-buffered saline (PBS) at 4 °C. After washes with 0.01% Triton-X100 in PBS, the retinas were incubated with the fluorophore-conjugated antibodies (Invitrogen) for 4 h at room temperature, washed, post-fixed with 4% PFA and mounted with Vectashield.
Immediately after dissection, mouse brains were fixed in 4% PFA overnight and then included in low-temperature melting agarose and 100-μm-thick sections were cut (VT1200s vibratome; Leica, Wetzlar, Germany). Free-floating sections were incubating overnight with the primary antibodies diluted in 5% donkey serum, 2% BSA and 0.3% Triton-X100 in PBS at 4 °C. After washes with 0.01% Triton-X100 in PBS, the sections were incubated with the fluorophore-conjugated antibodies (Invitrogen) for 4 h at room temperature, washed, post-fixed with 4% PFA and mounted with Vectashield.
Confocal microscopy was performed using a confocal microscope (TCS SP5, Leica), with the ImageJ software (NIH, New York, NY) used for image analysis.
For lesion quantification, 100-μm thick vibratome sections of brain were prepared and stained for endothelial markers as described above. For each brain, at least 10 sections were cut, and z-stacks were acquired with a ×10 objective. After maximal projection, the numbers and the areas of the lesions were manually measured by a blinded operator, using the ImageJ software.
Passive tissue clearing
Mice of strain and age as indicated in the text were anaesthetized by intraperitoneal injection of Avertin (20 mg/kg) and perfused with 4% PFA in PBS. The brains were carefully dissected out from the skull and post-fixed overnight by immersion in 4% PFA at 4 °C. The next day brains were washed in PBS and processed for sectioning.
Passive tissue clearing was carried out as previously described51, with some modifications. Briefly, vibratome coronal sections of cerebellum (1-mm thick) were incubated overnight at 4 °C in hydrogel solution (4% Acrylamide, 0.25% VA-044 in PBS). Sections were then transferred in cold microwave reaction vials and hydrogel solution was replaced with fresh solution. Tubes were sealed using a cap with rubber septum. Before starting the polymerization, hydrogel solution was degassed by bubbling nitrogen through the septum for 2 min on ice. Samples were then placed at 37 °C to activate polymerization. After 2 h, excess acrylamide was removed and sections were incubated overnight in clearing solution (8% sodium dodecylsulfate (SDS), 0.01% Sodium Azide in water, pH 8.5) at 37 °C. The clearing solution was then replaced and passive clearing was continued for 72 h at 37 °C. The cleared sections were then washed in PBS containing 0.1% Triton X100 and 0.01% Sodium Azide (washing buffer) for 48 h, with at least four changes of washing buffer. To enhance both clearing and washing efficacy, the buffer-to-section volume ratio was always >50.
Immunostaining was performed at room temperature as follows. Sections were incubated with the indicated antibody in washing buffer supplemented with 5% donkey serum for 72 h. Samples were then washed for 30 h and incubated, for 72 h, with the appropriate secondary antibody (Alexa 647 conjugated) diluted in washing buffer. Finally, samples were washed for 30 h.
Sections were then incubated and, subsequently, mounted in refractive index matching solution (88% w/v Hystodenz in water) for confocal imaging with a Leica SP8 microscope. Three-dimensional reconstructions were created using the Arivis Vision4D software and movies were assembled with Photoshop.
Brain endothelial cell isolation and FACS sorting
Endothelial cells were isolated from the brains using a dissociator (gentleMACS; 130-093-235; Miltenyi) and the Adult Brain Dissociation Kits (130-107-677; Miltenyi), following the manufacturer’s protocol. After dissociation, the cells were re-suspended in PBS with 2% foetal bovine serum and 2 mM EDTA and incubated for 30 min with an APC-conjugated anti-Cd31 antibody for FACS sorting. The sorting was performed on a MoFlo (Beckman Coulter Inc., Brea, CA, USA) cell sorter.
Intracranial injection of cells and Matrigel plug assay
Endothelial cells from either Cdh5(PAC)-Cre-ERT2/Ccm3f/f or Cdh5(PAC)-Cre-ERT2/Ccm3f/f/R26R-Confetti mice at P7 were isolated as described above. After dissociation, endothelial cells were enriched by depletion of CD45-positive cells with CD45 MicroBeads (30-052-301; Miltenyi Biotech), followed by positive selection using CD31 MicroBeads (30-097-418; Miltenyi Biotech). The final cell pellets were washed with twice and then re-suspended in PBS.
For intracranial injection, 30,000cells/μl were re-suspended and 2 μl were injected into the brain of adult wild-type or Cdh5(PAC)-Cre-ERT2/R26R-Confetti mice with a stereotaxic apparatus with the following coordinates: AP 1 mm, L 1 mm, D 2 mm. In parallel experiments, 500,000 cells isolated from P7 Cdh5(PAC)-Cre-ERT2/Ccm3f/f mice were re-suspended in 500 μl of Matrigel and implanted subcutaneously to Cdh5(PAC)-Cre-ERT2/R26R-Confetti adult mice.
Indirect measure of cell proliferation: cell counting
The endothelial cells Ccm3+/+, Ccm3−/− and Ccm3−/− to which has been re-added the human Ccm3 gene were plated at 60,000/cm2 and counted at different time points (24, 48, 72 h) to assess their proliferation. After having been harvested, the cells were stained with the Erythrosin B and counted at an optical microscope through the Burker’s chamber.
FACS analysis: Ki67 and PI staining
The protocol is intended for 3 × 106 cells and adapted from Vignon et al.52. After having been harvested, the cells were washed in PBS 1× and spun down at 500 × g for 5 min. The pellet recovered was resuspended in PBS 1× and fixed by adding pure cold ethanol 100% (1 PBS 1×:3 EtOH 100%), dropwise while vortexing. The cells were left in fixative at least for 30 min on ice. Following two washes with PBS 1×, 1% FBS SA and 0,25% Triton X-100 (PFT), the cells were stained in 300 μl of anti-mouse/rat Ki67 (Invitrogen by Thermo Fisher Scientific, clone SolA15), diluted 1:100 in PFT, for 5 h at room temperature under constant rotation. A control tube was prepared with 300 μl of anti-rat 647 diluted 1:400 in PFT. After two washes with PFT, the cells were stained in 300 μl of PFT with anti-rat 647 antibody from Jackson, diluted 1:400, followed by incubation for 1 h at room temperature, in the dark, under constant rotation. Cells were washed twice with PBS 1×, centrifuged for 5 min at 500 × g and resuspended in 1 ml of the intercalating fluorescent dye PI (2.5 μg/ml) plus RNase A (250 μg/ml). After an overnight incubation at 4 °C, FACS analysis was executed on the Attune NxT Life Technologies machine.
FACS analysis: BrdU and PI staining
The protocol is intended for 3 × 106 cells. While growing, the cells have been pulsed in MCDB131 medium containing 33 μM of BrdU. After having been harvested, the cells were washed in PBS 1× and spinned down at 500 × g for 5 min. The pellet recovered was resuspended in PBS 1× and fixed by adding pure cold ethanol 100% (1 PBS 1× : 3 EtOH 100%), dropwise while vortexing. The cells were left in fixative at least for 30 min on ice. Following one wash with PBS 1×/BSA 1%, the cells were resuspended in 1 ml of denaturing solution (2 N HCl) and incubated at room temperature for 25 min. After addition of 3 ml of 0.1 M Sodium Borate (Na2B4O7) and incubation for 2 min at room temperature, the cells were spinned down at 500 × g for 5 min and washed twice with PBS 1×/ BSA 1%. The pellet was resuspended in 100 μl of anti-BrdU (purified mouse anti-BrdU, BD Biosciences, cod.347580), diluted 1:5 in PBS 1×/BSA 1%, for 2 h at room temperature, light protected, under constant rotation. A control tube was prepared with 300 μl of anti-mouse 488 diluted 1:400 in PBS 1×. After one wash with PBS 1×/BSA 1%, the cells were stained in 300 μl of PBS 1× with anti-mouse 488 antibody from Jackson, diluted 1:400, followed by incubation for 1 h at room temperature, in the dark, under constant rotation. Cells were then washed once with PBS 1×/BSA 1%, centrifuged for 5 min at 500 × g and resuspended in 1 ml of the intercalating fluorescent dye PI (2.5 μg/ml) plus RNase A (250 μg/ml). After an overnight incubation at 4 °C, FACS analysis was executed on the Attune NxT Life Technologies machine.
Endothelial cell culture and treatments
For the in vitro experiments, the Ccm3+/+and Ccm3−/− immortalised lung endothelial cell lines were used24. The cells were grown in MCDB-131 (GIBCO, Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM glutamine, 10% North America foetal bovine serum (HyClone), 20 μg/ml endothelial cell growth supplement (E2759, Sigma-Aldrich), heparin (40 μg/ml, from porcine intestinal mucosa; Sigma) and penicillin/streptomycin (100 units/l; Sigma). The starvation medium was MCDB-131 (GIBCO) with 2 mM glutamine and 1% BSA.
For experiments with BMP6 and inhibitors, the cells were starved overnight, pre-incubated with either 1 μM K0228853 or 1 μM DMH136,39 for 1 h before stimulation with 100 ng/ml BMP6. The BMP6 and inhibitors were replaced daily over 5 days, and then the cells were lysed and analysed. In the same way, for the migration experiments, the cells were starved, pre-incubated with the inhibitors and then stimulated with BMP6. Just before stimulation, a wound was made, and after 48 h the cells were fixed and analysed.
For the experiments with conditioned medium, the cells were starved overnight and then incubated with complete medium that had been conditioned for 48 h by either the Ccm3+/+ or Ccm3−/− cell cultures. The medium was replaced after 3 days, and the cells analysed after a further 3 days.
For the cell migration experiments, the cells were starved, pre-incubated with 1 μM DMH1 in medium for 1 h and then incubated with the conditioned medium from Ccm3−/− or Ccm3+/+ cell cultures either without or with 1 μM DMH1. Just before stimulation, a wound was made, and after 48 h the cells were fixed and analysed.
Cloning, recombinant lentiviruses and gene transduction
The plasmid encoding LifeAct-EGFP was a kind gift from Professor Wedlich-Söldner54. To construct LifeAct-mCherry, the EGFP tag was excised by double digestion with the AgeI and BsrgI restriction enzymes, and the mCherry was ligated using the same sites. LifeAct-EGFP and LifeAct-mCherry were subsequently sub-cloned into the lentiviral vector (pFUGW). The plasmids containing the LifeAct-mCherry or LifeAct-EGFP fusion fragments were double-digested with XbaI and NheI, and subsequently the LifeAct-EGFP or LifeAct-mCherry fusions were gel-purified and sub-cloned into the lentiviral vector pFUGW using XbaI cloning sites. Recombinant lentiviruses were produced by triple transfection of the packaging 293T cells with the lenti FUGW carrying the gene of interest, packaging vectors (pCMV delta R8.2) and the envelope vector (pMD2.G) carrying the VSV glycoprotein (purchased from Addgene, Cambridge, MA 02139, USA). The virus was concentrated by ultracentrifugation at 50,000 × g for 90 min at 4 °C, and the pellet was stored at −80 °C until use.
Generation of cell lines
To generate Ccm3+/+and Ccm3−/− cells expressing either LifeAct-EGFP or LifeAct-mCherry, Ccm3+/+ and Ccm3−/− were transduced with the recombinant lentiviruses. In brief, the recombinant lentiviruses were re-suspended in serum-free MCDB-131 medium and added to the cells for 1 h at 37 °C.
To generate Ccm3−/− cells re-expressing mGFP-tagged CCM3, Ccm3−/− were transduced with the recombinant lentivirus Lenti ORF clone mGFP-tagged PDCD10 (OriGene Technologies Inc). In brief, the recombinant lentiviruses were re-suspended in serum-free MCDB-131 medium and added to the cells for 1 h at 37 °C. To increase the number of the cells, the cells were then passaged four times.
Ccm3 +/+and Ccm3 −/− cell co-cultures
Ccm3+/+and Ccm3−/− cells that expressed either LifeAct-EGFP or LifeAct-mCherry were mixed as single-cell suspensions (1:1) and plated and cultured under standard conditions. Usually the spheroids were analysed after 7 days. For cell isolation, the spheroids were removed from the monolayer following gentle shaking of the plate and collected and trypsinised. The single-cell suspensions obtained were immediately sorted by FACS for EGFP and mCherry expression, and then the cells were lysed and analysed for gene expression. For the experiments of spheroids detachment and transfer onto established monolayers, first the labelled Ccm3−/− cells were co-cultured with non-labelled Ccm3+/+ cells. After 7 days, the established spheroids were detached by shaking and placed on the top of an established monolayer of labelled Ccm3+/+ cells.
Generation of endothelial spheroids
Endothelial cell spheroids were generated as previously described36.
Briefly, 3000 lung-derived immortalised endothelial cells were suspended in culture medium containing 0.20% (w/v) methyl cellulose and seeded in non-adherent round-bottom 96-well plates (Greiner). Under these conditions, all suspended cells contribute to the formation of one single rounded endothelial cell spheroid per well. These standardised spheroids were cultured for 6 days, then were harvested from 96-well plate, washed with PBS and processed for total RNA extraction.
Wound-healing assay with two cell types and live imaging
Ccm3+/+and Ccm3−/− cells that expressed either LifeAct-EGFP or LifeAct-mCherry were seeded in each side of an ibidi silicon insert and grown till confluence. Time-lapse images were acquired either immediately after the insert removal or after cells were allowed to close the wound. Live-cell imaging was performed with Leica TCS SP8 confocal (Leica, Germany) under 37 °C and 5% CO2. Images were acquired using either HC PL APO 1.3 oil ×40 or HCX PL APO ×63 1.4 oil objective lenses (Leica, Germany), respectively.
Gene expression analysis
Total RNA was isolated using the RNeasy Mini Kits (Qiagen Inc., Santa Clarita, CA, USA) and 500 ng total RNA was reverse transcribed with random hexamers (High-Capacity cDNA Archive Kits; Applied Biosystems), following the manufacturer’s instructions. The cDNAs were amplified using the TaqMan gene expression assay (Applied Biosystems, Foster City, CA, USA) and an ABI/Prism 7900 HT thermocycler. The following TaqMan Assays have been used: Klf4 mm00516104_m1; Fsp1 mm00803371_m1; Cd44 mm01277163_m1; Fn1 mm01256734_m1; Cldn5 mm00727012_s1; Ccm3 mm00727342_s1; Sca1 mm00726565_s1; Id1 mm00775963_g1; and as housekeeping genes: 18s Hs99999901_s1; Gapdh mm99999915_g1; and Hprt1 mm00446968_m1.
The cells were lysed in boiling modified Laemmli sample buffer (2% SDS, 20% glycerol, 125 mM Tris-HCl, pH 6.8). Equal amounts of protein were loaded onto gels and separated by SDS–polyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (Protran; Whatman). After blocking with 5% BSA and incubations with the primary and HRP-linked secondary antibodies, specific binding was quantified using a chemiluminescence system (GE Healthcare).
In situ hybridisation
In situ hybridisation was carried out on brain cryosections (RNAScope assay; AcdBio), following the manufacturer’s recommendations. The Mm-Procr probe (410321) was used for the hybridisation of Procr, followed by detection (RNAScope 2.5 HD Detection Reagents – RED; 322360).
Statistical significance was determined using a one-way analysis of variance (ANOVA) tests followed by Tukey’s post hoc analysis. For the growth curve experiment, two-way ANOVA test were followed by Tukey’s post hoc analysis for multiple comparison within each time point.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Wong, J. H., Awad, I. A. & Kim, J. H. Ultrastructural pathological features of cerebrovascular malformations: a preliminary report. Neurosurgery 46, 1454–1459 (2000).
Labauge, P., Denier, C., Bergametti, F. & Tournier-Lasserve, E. Genetics of cavernous angiomas. Lancet Neurol. 6, 237–244 (2007).
Storkebaum, E., Quaegebeur, A., Vikkula, M. & Carmeliet, P. Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nat. Neurosci. 14, 1390–1397 (2011).
Rigamonti, D. et al. Cerebral cavernous malformations. Incidence and family occurrence. N. Engl. J. Med. 319, 343–347 (1988).
Clatterbuck, R. E., Eberhart, C. G., Crain, B. J. & Rigamonti, D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J. Neurol. Neurosurg. Psychiatry 71, 188–192 (2001).
Choquet, H., Pawlikowska, L., Lawton, M. T. & Kim, H. Genetics of cerebral cavernous malformations: current status and future prospects. J. Neurosurg. Sci. 59, 211–220 (2015).
McDonald, D. A. et al. Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum. Mol. Genet. 23, 4357–4370 (2014).
Pagenstecher, A., Stahl, S., Sure, U. & Felbor, U. A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum. Mol. Genet. 18, 911–918 (2009).
Akers, A. L., Johnson, E., Steinberg, G. K., Zabramski, J. M. & Marchuk, D. A. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum. Mol. Genet. 18, 919–930 (2009).
Dejana, E., Hirschi, K. K. & Simons, M. The molecular basis of endothelial cell plasticity. Nat. Commun. 8, 14361 (2017).
Cunha, S. I., Magnusson, P. U., Dejana, E. & Lampugnani, M. G. Deregulated TGF-β/BMP signaling in vascular malformations. Circ. Res. 121, 981–999 (2017).
Basile, D. P. & Yoder, M. C. Circulating and tissue resident endothelial progenitor cells. J. Cell. Physiol. 229, 10–16 (2014).
Kovacic, J. C. & Boehm, M. Resident vascular progenitor cells: an emerging role for non-terminally differentiated vessel-resident cells in vascular biology. Stem Cell Res. 2, 2–15 (2009).
Dejana, E. & Lampugnani, M. G. Endothelial cell transitions. Science 362, 746–747 (2018).
O’Brien, C. A., Kreso, A. & Dick, J. E. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 19, 71–77 (2009).
Al-Hajj, M. & Clarke, M. F. Self-renewal and solid tumor stem cells. Oncogene 23, 7274–7282 (2004).
Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256–260 (2015).
Chen, L. et al. Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke 40, 1474–1481 (2009).
Zhu, Y. et al. Loss of endothelial programmed cell death 10 activates glioblastoma cells and promotes tumor growth. Neuro Oncol. 18, 538–548 (2016).
Garaci, F. et al. Cerebral cavernous malformations associated to meningioma: High penetrance in a novel family mutated in the PDCD10 gene. Neuroradiol. J. 28, 289–293 (2015).
Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134–144 (2010).
Livet, J. et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 56–62 (2007).
Wang, Y. et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483–486 (2010).
Bravi, L. et al. Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. Proc. Natl Acad. Sci. USA 112, 8421–8426 (2015).
Schleider, E. et al. Evidence for anti-angiogenic and pro-survival functions of the cerebral cavernous malformation protein 3. Neurogenetics 12, 83–86 (2011).
Lauenborg, B. et al. Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS 118, 719–728 (2010).
Fidalgo, M. et al. Adaptor protein cerebral cavernous malformation 3 (CCM3) mediates phosphorylation of the cytoskeletal proteins Ezrin/Radixin/Moesin by mammalian Ste20-4 to protect cells from oxidative stress. J. Biol. Chem. 287, 11556–11565 (2012).
Lambertz, N. et al. Downregulation of programmed cell death 10 is associated with tumor cell proliferation, hyperangiogenesis and peritumoral edema in human glioblastoma. BMC Cancer 15, 759 (2015).
Lin, C., Meng, S., Zhu, T. & Wang, X. PDCD10/CCM3 acts downstream of γ-protocadherins to regulate neuronal survival. J. Biol. Chem. 285, 41675–41685 (2010).
Chen, L. et al. Apoptotic functions of PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke 40, 1474–1481 (2009).
Zhang, H. et al. PDCD10 interacts with STK25 to accelerate cell apoptosis under oxidative stress. Front. Biosci. (Landmark Ed.) 17, 2295–2305 (2012).
Salman, R. A.-S. et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study. Lancet Neurol. 11, 217–224 (2012).
Gross, B. A., Du, R., Orbach, D. B., Scott, R. M. & Smith, E. R. The natural history of cerebral cavernous malformations in children. J. Neurosurg. Pediatr. 17, 123–128 (2016).
Manavski, Y. et al. Clonal expansion of endothelial cells contributes to ischemia-induced neovascularization. Circ. Res. 122, 670–677 (2018).
Detter, M. R., Snellings, D. A. & Marchuk, D. A. Cerebral cavernous malformations develop through clonal expansion of mutant endothelial cells. Circ. Res. https://doi.org/10.1161/CIRCRESAHA.118.313970 (2018).
Maddaluno, L. et al. EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature 498, 492–496 (2013)
Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).
Cuttano, R. et al. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations. EMBO Mol. Med. 8, 6–24 (2016).
Ao, A., Hao, J., Hopkins, C. R. & Hong, C. C. DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS ONE 7, e41627 (2012).
Mouillesseaux, K. P. et al. Notch regulates BMP responsiveness and lateral branching in vessel networks via SMAD6. Nat. Commun. 7, 13247 (2016).
Lee, H.-W. et al. Alk2/ACVR1 and Alk3/BMPR1A provide essential function for bone morphogenetic protein-induced retinal angiogenesis. Arterioscler. Thromb. Vasc. Biol. 37, 657–663 (2017).
Tilki, D., Hohn, H.-P., Ergü, B., Rafii, S. & Leyman Ergü, S. Emerging biology of vascular wall progenitor cells in health and disease. Trends Mol. Med. 15, 501–509 (2009).
Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611–629 (2017).
Wakabayashi, T. et al. CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative properties. Cell Stem Cell 22, 384–397 (2018).
Yu, Q. C., Song, W., Wang, D. & Zeng, Y. A. Identification of blood vascular endothelial stem cells by the expression of protein C receptor. Cell Res. 26, 1079–1098 (2016).
Malinverno, M. et al. Peg3/PW1 is a marker of a subset of vessel associated endothelial progenitors. Stem Cells https://doi.org/10.1002/stem.2566 (2017).
Boulday, G. et al. Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice. J. Exp. Med. 208, 1835–1847 (2011).
Corada, M. et al. Fine tuning of Sox17 and canonical Wnt coordinates the permeability properties of the blood-brain barrier. Circ. Res. 124, 511–525 (2019).
Wang, D. et al. Identification of multipotent mammary stem cells by protein C receptor expression. Nature 517, 81–84 (2014).
Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128–134 (2018).
Yang, B. et al. Single-cell phenotyping within transparent intact tissue through whole-body clearing. Cell 158, 945–958 (2014).
Vignon, C. et al. Flow cytometric quantification of all phases of the cell cycle and apoptosis in a two-color fluorescence plot. PLoS ONE 8, e68425 (2013).
Benn, A. et al. Role of bone morphogenetic proteins in sprouting angiogenesis: differential BMP receptor-dependent signaling pathways balance stalk vs. tip cell competence. FASEB J. 31, 4720–4733 (2017).
Riedl, J. et al. Lifeact: a versatile marker to visualize F-actin. Nat. Methods 5, 605–607 (2008).
This study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC IG 18683) and AIRC 5×1000 call ‘Metastatic disease: the key unmet need in oncology’ to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture Airc), by The Swedish Research Council, contract No. 2013-9279, and the Knut and Alice Wallenberg Foundation, by the European Research Council (project EC-ERC-VEPC, contract 742922), by Initial Training Networks (ITN) Brain Barrier Training (BtRAIN), contract No. 675619, by CARIPLO Foundation project : 2014-1038 and Project 2016-0461, Be Brave for Life Foundation Micro Grant. We are grateful to Dr. Maria Grazia Totaro and Dr. Arianna Quintè of the Cytometry Unit of Cogentech for excellent technical support. We thank Dr Christopher P. Berrie for editorial assistance. We are indebted to Professor Ralph Adams for providing Cdh5(PAC)-CreERT2 mice.
The authors declare no competing interests.
Peer review information: Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.